752 related articles for article (PubMed ID: 18314612)
1. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
Sotlar K
Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
[TBL] [Abstract][Full Text] [Related]
2. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis, clinical features, and treatment advances in mastocytosis.
Pardanani A; Akin C; Valent P
Best Pract Res Clin Haematol; 2006; 19(3):595-615. PubMed ID: 16781490
[TBL] [Abstract][Full Text] [Related]
4. Mastocytosis.
Metcalfe DD
Novartis Found Symp; 2005; 271():232-42; discussion 242-9. PubMed ID: 16605139
[TBL] [Abstract][Full Text] [Related]
5. Novel approaches in the treatment of systemic mastocytosis.
Quintas-Cardama A; Aribi A; Cortes J; Giles FJ; Kantarjian H; Verstovsek S
Cancer; 2006 Oct; 107(7):1429-39. PubMed ID: 16948123
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the understanding of mastocytosis: the role of KIT mutations.
Orfao A; Garcia-Montero AC; Sanchez L; Escribano L;
Br J Haematol; 2007 Jul; 138(1):12-30. PubMed ID: 17555444
[TBL] [Abstract][Full Text] [Related]
7. KIT mutations in mastocytosis and their potential as therapeutic targets.
Gotlib J
Immunol Allergy Clin North Am; 2006 Aug; 26(3):575-92. PubMed ID: 16931294
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.
Böhm A; Sonneck K; Gleixner KV; Schuch K; Pickl WF; Blatt K; Peter B; Herrmann H; Schernthaner GH; Pehamberger H; Rabitsch W; Sperr WR; Valent P
Exp Hematol; 2010 Sep; 38(9):744-55. PubMed ID: 20553795
[TBL] [Abstract][Full Text] [Related]
9. Mastocytosis - an update.
Amon U; Hartmann K; Horny HP; Nowak A
J Dtsch Dermatol Ges; 2010 Sep; 8(9):695-711; quiz 712. PubMed ID: 20678151
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives.
Arock M; Valent P
Expert Rev Hematol; 2010 Aug; 3(4):497-516. PubMed ID: 21083038
[TBL] [Abstract][Full Text] [Related]
11. KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).
Peter B; Hadzijusufovic E; Blatt K; Gleixner KV; Pickl WF; Thaiwong T; Yuzbasiyan-Gurkan V; Willmann M; Valent P
Exp Hematol; 2010 Sep; 38(9):782-91. PubMed ID: 20685234
[TBL] [Abstract][Full Text] [Related]
12. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms.
Zermati Y; De Sepulveda P; Féger F; Létard S; Kersual J; Castéran N; Gorochov G; Dy M; Ribadeau Dumas A; Dorgham K; Parizot C; Bieche Y; Vidaud M; Lortholary O; Arock M; Hermine O; Dubreuil P
Oncogene; 2003 Feb; 22(5):660-4. PubMed ID: 12569358
[TBL] [Abstract][Full Text] [Related]
13. KIT and mastocytosis.
Lim KH; Pardanani A; Tefferi A
Acta Haematol; 2008; 119(4):194-8. PubMed ID: 18566536
[TBL] [Abstract][Full Text] [Related]
14. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.
Isotani M; Tamura K; Yagihara H; Hikosaka M; Ono K; Washizu T; Bonkobara M
Vet Immunol Immunopathol; 2006 Nov; 114(1-2):168-72. PubMed ID: 16908071
[TBL] [Abstract][Full Text] [Related]
15. Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia.
Corless CL; Harrell P; Lacouture M; Bainbridge T; Le C; Gatter K; White C; Granter S; Heinrich MC
J Mol Diagn; 2006 Nov; 8(5):604-12. PubMed ID: 17065430
[TBL] [Abstract][Full Text] [Related]
16. Systemic mastocytosis: current classification and novel therapeutic options.
Barbie DA; Deangelo DJ
Clin Adv Hematol Oncol; 2006 Oct; 4(10):768-75. PubMed ID: 17099633
[TBL] [Abstract][Full Text] [Related]
17. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.
Longley BJ; Tyrrell L; Lu SZ; Ma YS; Langley K; Ding TG; Duffy T; Jacobs P; Tang LH; Modlin I
Nat Genet; 1996 Mar; 12(3):312-4. PubMed ID: 8589724
[TBL] [Abstract][Full Text] [Related]
18. Mastocytosis: pathology, genetics, and current options for therapy.
Valent P; Akin C; Sperr WR; Mayerhofer M; Födinger M; Fritsche-Polanz R; Sotlar K; Escribano L; Arock M; Horny HP; Metcalfe DD
Leuk Lymphoma; 2005 Jan; 46(1):35-48. PubMed ID: 15621779
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms.
Valent P; Sperr WR; Schwartz LB; Horny HP
J Allergy Clin Immunol; 2004 Jul; 114(1):3-11; quiz 12. PubMed ID: 15241337
[TBL] [Abstract][Full Text] [Related]
20. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
Pedersen M; Rönnstrand L; Sun J
Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
